Telaprevir and Buprenorphine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Telaprevir
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Let's talk about taking buprenorphine (a pain or opioid-dependence medicine) together with telaprevir (a hepatitis C medicine). Telaprevir slows down the liver enzyme that normally breaks down buprenorphine. That means more buprenorphine can build up in your body, which can lead to stronger opioid effects like heavy drowsiness or slowed, shallow breathing. On top of that, both medicines can affect your heart's rhythm (the QT interval), so using them together can add to that risk.
The good news: your care team can manage this. They may adjust your buprenorphine dose, check your heart rhythm, and watch you more closely. Please don't change anything on your own. Just talk with your doctor or pharmacist.
Effect: Telaprevir, a potent CYP3A4 inhibitor, reduces buprenorphine metabolism, increasing buprenorphine exposure (higher plasma concentrations) and the risk of opioid adverse effects, including sedation and respiratory depression. Both agents also prolong the QT interval, producing additive cardiac conduction risk.
- Direction: Increased buprenorphine effect (neither is a prodrug here).
- Severity/Evidence: Major; probable. Onset unspecified.
- Management: Monitor ECG/QT and observe frequently for sedation and respiratory depression. Consider reducing buprenorphine dose until stable effects are achieved. On telaprevir discontinuation, anticipate reduced buprenorphine levels and monitor for withdrawal; a dose increase may be needed. Prefer formulations allowing precise titration.
What happens
An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events
Interaction Deep Dive
Combining buprenorphine with a CYP3A4 inhibitor can raise buprenorphine plasma concentrations, potentially extending opioid effects such as respiratory depression. The likelihood of QT prolongation also rises when drugs that influence cardiac conduction are given together. Should these agents be used together, watch the patient carefully for signs that the QT interval is lengthening. It may be advisable to lower the buprenorphine dose until drug effects stabilize, while frequently checking for sedation and respiratory depression. If a CYP3A4 inhibitor is stopped in someone on buprenorphine, consider raising the buprenorphine dose until stable effects are reached, and observe for indications of opioid withdrawal2. Should dose adjustment prove impossible once the CYP3A4 inhibitor is absent, switch the patient to a buprenorphine formulation that allows finer dose control. For patients moved from transmucosal buprenorphine taken with CYP3A4 inhibitors, verify that the plasma buprenorphine concentration delivered by subQ buprenorphine is sufficient. For those already receiving subQ buprenorphine who then need a CYP3A4 inhibitor, watch for indications of over-medication. Where signs and symptoms of buprenorphine toxicity or overdose appear yet the accompanying medication cannot be lowered or stopped, decrease the buprenorphine dose. If the available doses do not allow the target dose to be reached, halt treatment and manage the patient with a buprenorphine formulation permitting more precise dose adjustments 1.
Why it happens (mechanism)
Additive QT interval prolongation; inhibition of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
Keep taking both medicines as prescribed unless your care team tells you otherwise. Here is what a team typically does:
- Monitor your heart rhythm (an ECG for QT interval) since both drugs can affect it.
- Watch closely for excessive drowsiness or slow, shallow breathing.
- Your buprenorphine dose may be adjusted and individualized until effects are stable.
- If the hepatitis C medicine is later stopped, your team may raise the buprenorphine dose again and watch for withdrawal signs.
Tell your pharmacist or prescriber about any strong sleepiness, breathing changes, dizziness, or fainting right away.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
2 reports — tap to read
a) In a study of healthy volunteers (N=12), giving oral buprenorphine together with voriconazole produced significant increases in the mean AUC(0 to 18 hours) of buprenorphine by 4.3-fold (from 0.43 to 2.1 nanograms (ng) x hr/mL), Cmax by 3.9-fold (from 0.057 to 0.22 ng/mL), half-life (from 9.1 to 14.5 hours), and urinary clearance (from 0.31 to 0.73 L/hr). Voriconazole likewise significantly raised the exposure of the active metabolite norbuprenorphine, with AUC(0 to 18 hours) rising by almost 4-fold and Cmax by 3.3-fold, and lowered renal clearance (from 7.2 to 2.9 L/hr). Participants reported mild dizziness and nausea in both phases. Subjects were given either placebo or voriconazole 400 mg twice daily on day 1, then 200 mg twice daily on days 2 to 5, followed by a 4-week washout period before crossing over to the alternative regimen. On the fifth day, every subject received a single dose of buprenorphine, 0.2 mg orally, or 3.6 mg during the placebo phase 3.
b) The impact of concurrently administered CYP3A4 inhibitors on buprenorphine exposure in patients receiving subQ buprenorphine has not been investigated; nevertheless, such interactions have been demonstrated in studies employing transmucosal buprenorphine. The effects of buprenorphine may depend on the route of administration 1.
Common questions
Can I take Telaprevir and Buprenorphine together?
Telaprevir can raise buprenorphine levels and add to QT-prolongation risk, so your care team may adjust the buprenorphine dose and monitor your breathing and heart rhythm more closely. Do not change your doses on your own; talk with your doctor or pharmacist. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Telaprevir and Buprenorphine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Telaprevir and Buprenorphine interaction managed?
Keep taking both medicines as prescribed unless your care team tells you otherwise. Here is what a team typically does: Monitor your heart rhythm (an ECG for QT interval) since both drugs can affect it. Watch closely for excessive drowsiness or slow, shallow breathing. Your buprenorphine dose may be adjusted and individualized until effects are stable. If the hepatitis C medicine is later stopped,… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Telaprevir or Buprenorphine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
- Fihlman M, Hemmila T, Hagelberg NM, et al: Voriconazole greatly increases the exposure to oral buprenorphine. Eur J Clin Pharmacol 2018; 74(12):1615-1622. PubMed
Keep reading about Buprenorphine
Keep reading about Telaprevir
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist